December 14, 2017

Cosentyx: Good News For Ankylosing Spondylitis Patients

By Editor

Spine Community News: Doctors recently updated the results of the MEASURE 1 extension clinical trial designed to evaluate Cosentyx (secukinumab) for the treatment of ankylosing spondylitis (AS) at the American College of Rheumatology 2017 Annual Meeting. Cosentyx effectively improved symptoms in AS patients up to four years.

About Cosentyx (secukinumab)

Interleukin-17 (IL-17) is a protein produced by immune cells that functions as a messenger between cells playing an important role in inflammation and the symptoms associated with AS, including morning stiffness, limited spine motion, and overall fatigue. Cosentyx is an anti-IL-17 monoclonal antibody that blocks the effects of IL-17 leading to an improvement in IL-17 associated symptoms. Cosentyx is currently approved for use in AS, psoriasis and psoriatic arthritis.

The MEASURE extension trial clinical evaluated 371 patients with active AS and treated them with two different doses of Cosentyx or placebo for a 4 year period and directly compared their outcomes. All AS patients were evaluated both clinically and radiographically in regard to activity of their AS.

Overall 274 patients were treated with two doses of Cosentyx and treatment was well tolerated. The study authors reported that patients receiving the higher Cosentyx dose experienced greater improvement in their signs and symptoms of AS than individuals treated with the lower Cosentyx dose or placebo. Cosentyx treated patients also had fewer spinal radiographic changes suggestive of progressive AS.

The study authors concluded that the higher Cosentyx dose of 150 mg was more effective in controlling AS symptoms and slowed radiographic progression sustaining these improvements for at least 4 years. Cosentyx represents and effective treatment option for AS patients.

David Borenstein, MD
Executive Editor TheSpineCommunity.com

Reference:

Braun J et al. Secukinumab demonstrates Low Radiographic Progression ans Sustained Efficacy through 4 Years ub patients wth Active Ankylosing Spondylitis {abstract]. Arthritis Rheumatol 2017;69 (suppl10)

Tags: Ankylosing Spondylitis, AS, clinical trial, Cosentyx, extension, interleukin 17, MEASURE 1, News Tips and Features, secukinumab, Uncategorized

CONDITIONS OF THE GI TRACT